Niroda Therapeutics

Niroda Therapeutics is a clinical-stage biotechnology company redefining non-opioid pain treatment through precision sodium-channel modulation. Its pipeline is anchored by a potentially best-in-class NaV1.8 inhibitor and expanded through a rational combination strategy, including the first-in-clinic NaV1.8 + NaV1.7 program. By targeting multiple validated pain pathways simultaneously, Niroda aims to deliver superior efficacy across acute and chronic pain indications. The company is backed by a syndicate of leading healthcare investors and brings together a team with deep expertise in pain drug development, ion-channel biology, and commercialization.